Protara Therapeutics, Inc.
NASDAQ:TARA
Overview | Financials
Company Name | Protara Therapeutics, Inc. |
Symbol | TARA |
Currency | USD |
Price | 2.59 |
Market Cap | 53,431,182 |
Dividend Yield | 0% |
52-week-range | 1.04 - 5.24 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jesse Shefferman |
Website | https://www.protaratx.com |
An error occurred while fetching data.
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD